Personalized medicine in diabetology in the context of consensual statement of the ADA/EASD 2015

1. Uličiansky V, Schroner Z, Galajda P et al. Algoritmus liečby diabetes mellitus 2. typu 2011 v klinickej praxi. Diabetes a obezita 2011; 11(22): 9–32.

2. Pozzilli P, Leslie RD, Chan J et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a phycisian´s personalized approach. Diabetes Metab Res Rev 2010; 26(4): 239–244.

3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes. A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364–1379.

4. Raz I, Ridle MC, Rosenstock J et al. Personalized Management of Hyperglycemia in Type 2 Diabetes. Reflection from a Diabetes Care Editors´ Expert Forum. Diabetes Care 2013; 36(6): 1779–1788.

5. Škrha J. Úskalí současných poznatků v terapii. In: Škrha J. Cesta diabetologie aneb Kde vše začíná a končí. Maxdorf Jessenius: Praha 2014: 61–87. ISBN 9788073453855.

6. Matthews DR. Wisdom-based and evidence-based medicine. Diabetes Obes Metab 2012; 14(Suppl 1): 1–2.

7. Uličiansky V. Personalizovaná medicína. In: Uličiansky V (ed). Diabetes mellitus v zrelom veku. Quick Print: Martin 2013: 34–46.

8. Topolčan O, Kinkorová J. Personalizovaná medicína. Klin Farmakol Far 2012; 26(3): 121–122.

9. Sadee W. Genomics and personalized medicine. Int J Pharm 2011; 415(1–2): 2–4.

10. Florence AT, Lee VHL: Personalised medicines: More tailored drugs, more tailored delivery. Int J Pharm 2011; 415(1–2): 29–33.

11. Chen R, Mias GI, Li-Pook-Than J et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148(6): 1293–1307.

12. Smith RJ, Nathan DM, Arslanian SA et al. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95(4): 1566–1574.

13. European Commission. Research & Innovation – Health. Towards Personalised Medicine. Dostupné z http: <http://ec.europa.eu/research/health/policy-issues-personalised-medicine_en.html>.

14. Mullan RJ, Montori VM, Shah ND et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009; 169(17): 1560–1568.

15. Ďuriš I, Hulín I, Bernardič M. Editorial. In: Ďuriš I, Hulín I, Bernardič M. Princípy internej medicíny 1. Slovak Academic Press: Bratislava 2001. ISBN 80–88908–69–8.

16. Nathan M, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52(1): 17–30.

17. Inzuchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1):140–149.

18. American Diabetes Association. Standards of medical care in diabetes – 2015. 6. Glycemic Targets. Diabetes Care 2015; 38(Suppl 1): S33–S40. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-S009>.

19. AACE/ACE Diabetes Guidelines. Endocr Pract 2015; 21(Suppl 1):4. Dostupné z WWW: <https://www.aace.com/files/dm-guidelines-ccp.pdf>.

20. Ismail-Beigi F, Moghissi E, Tiktin E et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011; 154(8): 554–559.

21. Uličiansky V. Algoritmus liečby diabetes mellitus 2. typu. Via medica: Košice 2008. ISBN 978–80–970058–3-2.

22. Staník J, Gašperíková D, Klimeš I. Monogénový diabetes mellitus. In: Staník J, Gašperíková D, Klimeš I. Monogénové poruchy sekrécie a účinku inzulínu. Univerzita Komenského: Bratislava 2015. ISBN 978–80–223–3803–5.

23. Schroner Z, Javorsky M, Tkacova R et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(1): 89–91.

24. Javorský M, Klimčáková L, Schroner Z et al. KCN11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 2012; 23(3): 245–249.

25. Tkáč I, Javorský M, Klimčáková L et al. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. Eur J Clin Pharmacol 2015; 71(1): 59–63.

26. Smushkin G, Sathananthan M, Sathananthan A et al. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012; 61(5): 1082–1089.

27. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 2008; 51(6): 921–925.

28. O Lillie E, Patay B, Diamant J et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011; 8(2): 161–173.

29. Nalysnyk L, Hemandez-Medina M, Krishnarajah G. Glycamic variability and complications in patients with diabetes mellitus: evidence from systemic review of the literature. Diabetes Obes Metab 2012; 12(4): 288–298.

30. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008; 31(Suppl 2): S150-S154.

31. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009, 58(4): 773–796.

32. Kahn SE, Cooper ME, Del Prato S. Pathopysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet 2014; 383(9922): 1068–1083.

33. Haluzík M. Průvodce léčbou diabetu 2. typu pro internisty. Mladá fronta: Praha 2015. ISBN 978–80–204–2405–1.

34. Del Prato S, LaSalle J, Matthaei S et al. Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Parthership for Effective Diabetes Management. Int J Clin Pract 2010; 64(3): 295–304.

35. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737–1743.

36. Okša A, Ponťuch P, Spustová V et al. Diabetická nefropatia: Diagnostika, prevencia a liečba. Odporúčané postupy Slovenskej nefrologickej spoločnosti a Slovenskej diabetologickej spoločnosti. Forum Diab 2013; 2(Suppl 1): S1-S6.

37. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl (2011) 2013; 3(1): 5–14.

38. Haluzík M. Léčba diabetiků s chronickým onemocněním jater. In: Haluzík M, Rychlík I (eds). Léčba pacientů s onemocněním ledvin a jater. Mladá fronta: Praha 2012: 115–125. ISBN 978–80–204–2671–0.

39. Romeo GR., Abrahamson MJ, Goldfine AB. Insulin Segretagogues: Sulfonylureas and Glinides. In: Umpierrez GE (ed) Therapy for Diabetes Mellitus and Related Disorders. 6th ed. American Diabetes Association 2014: 359–376. ISBN 978–1580405096.

40. Zoungas S, Chalmers J, Neal B et al. ADVANCE-ON Collaborative Group. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med 2014; 371(15):1392–1406.

41. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(8323):2072–2077.

42. Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014; 30(2): 94–97.

43. Schroner Z, Uličiansky V. Inhibítory dipeptidyl-peptidázy-4 – základná charakteristika a mechanizmus účinku. In: Schroner Z, Uličiansky V. Liečba diabetes mellitus 2. typu založená na účinku inkretínov. 2. rozšírené vyd. SchronerMed: Košice 2011: 41–62.ISBN 9788097071479.

44. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs. FDA and EMA assessment. N Engl J Med 2014; 370(9): 794–797.

45. Štulc T, Šedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010; 88(2): 125–131.

46. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24(2): 79–83.

47. Schweizer A, Dejager S, Foley JE et al. Assesing the cardio-vascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12(6): 485–494.

48. White WB, Cannon CHP, Heller SR et al. EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013; 369(14): 1327–1335.

49. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369(14):1317–1326.

50. Nainggolan L. TECOS: No Increase in HF Hospitalization With Sitagliptin. Medscape Medical News. Dostupné z WWW: <http://www.medscape.com/viewarticle/843830>.

51. Bays H. Sodium Glucose Co-transporter Type 2 (SGLP2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther 2013; 4(2): 195–220.

52. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14(1): 5–14.

53. Schroner Z. SGLT-2 inhibítory a iné nové trendy liečby diabetes mellitus 2. typu. In: Uličiansky V, Schroner Z, Galajda P et al. Diabetes mellitus v zrelom veku. Martin: Quick Print 2013: 93–106.

54. Uličiansky V. Nová stratégia v liečbe diabetu mellitus 2. typu – inhibícia renálnej reabsorpcie glukózy. Interná Med 2014; 14(4): 179–185.

55. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97(3): 1020–1031.

56. Schroner Z, Uličiansky V. Nová cesta v liečbe diabetes mellitus 2. typu – SGLT2 inhibítory. Diabetes a obezita 2014; 14(28): 31–35.

57. Stenlof K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15(4): 372–382.

58. Galajda P, Samoš M, Mokáň M et al. Nový SGLT2 inhibítor – empagliflozín. Diabetes a obezita 2014; 14(28): 37–46.

59. Häring HU, Merker L, Seewald-Becker E et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36(11): 3396–3404.

60. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122(Suppl 6):S37-S50.

61. Nauck M, Smith U. Increatin- based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin Endocrinol Metab 2009; 23(4): 513–523.

62. Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683): 39–47.

63. Stonehouse A, Walsh B, Cuddihy R. Exenatide Once-Weekly Clinical Development. Safety and Efficacy Across a Range of Background Therapies. Diabetes Technol Ther 2011; 13(10): 1063–1069.

64. Meier JJ. GLP‑1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8(12):728–742.

65. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013; 30(2):81–101.

66. Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management – exploring the concept of the basal-plus approach in clinical practice. Diabet Med 2013; 30(3): 276–288.

67. Fonseca V, Davidson J, Home P et al. Startins insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-targe trials. Curr Med Res Opin 2010; 26(7): 1621–1628.

68. Martinka E. Liečba inzulínom u pacientov s diabetes melltius 2. typu. In: Mokáň M, Martinka E, Galajda P a kol: Diabetes mellitus a vybrané metabolické ochorenia. Vydavateľstvo P+M: Martin 2008: 323–331. ISBN 978–80–969713–9-8,

69. Halimi S, Raskin P, Liebl A et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005; 27(Suppl B): S57-S74.

70. Holman RR, Thorne KI, Farmer AJ et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357(17): 1716–1730.

71. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013; 15(1): 3–14.

72. Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15(2): 175–184.

73. Gerstein HC, Bosch J, Dagenais GR et al. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Eng J Med 2012; 367(4): 319–328.